This study investigated long-term cardiac-related mortality as it relates to incidence of perioperative adverse cardiac events (excluding death) in the first 30 days after surgery among a short of patients who underwent non–cardiac-related surgery.
Following surgery for a non–cardiac-related matter, risk of long-term mortality was shown to nearly double due to perioperative adverse cardiac events (PACEs), reports Journal of the American Heart Association.
These outcomes were investigated among 202,584 consecutive patients who underwent noncardiac surgery between January 2011 and June 2019 at Samsung Medical Center in Seoul, Republic of Korea. For this study, PACEs were defined to be a composite end point comprising myocardial infarction, coronary revascularization, congestive heart failure, arrhythmic attack, acute pulmonary embolism, cardiac arrest, or stroke in the 30 days after surgery. Patients who died in the 30 days following their surgery were excluded from the final analysis.
“Cardiac complications are associated with perioperative mortality,” the authors wrote, “but PACEs that are associated with long-term mortality have not been clearly defined.”
Overall, there was a 90% greater risk of mortality (HR, 1.90; 95% CI, 1.74-2.09; P < .001) among the patients who experienced PACEs (n = 7994) compared with those who did not (n = 194,590). In addition, there was a 5.6-percentage-point difference in actual incidence of all-cause mortality when comparing outcomes among patients with PACEs and those without: 7.7% vs 2.1%.
The primary study end point was mortality in the first year, and it was also compared at the 3-year mark. Associations for variables—including male sex, age, diabetes status, current alcohol use, and European Society of Cardiology/European Society of Anaesthesiology intermediate‐to‐high surgical risk—and 1-year mortality were also determined.
The median (IQR) length of time between surgery and PACE was 2 (1-4) days, the mean (SD) patient ages were 62.2 (15.1) in the no-PACEs group and 64.8 (12.7) in the PACEs group, and rates of both hypertension and diabetes were higher in the PACEs group vs the no-PACEs group, at 48.6% vs 24.4% and 25.1% vs 11.0%, respectively. Follow-ups, meanwhile, were similar: The no-PACEs group had a median follow-up of 1125 (406-1959) days, and the PACEs group, 1063 (412-1824) days.
In addition to all-cause mortality, cardiovascular (CV) mortality was gauged at the 1-year mark. Again this was higher in the PACEs group: 0.9% vs 3.4% (HR, 1.81; 95% CI, 1.58-2.08; P < .001). And when 3-year rates for all-cause and CV mortality were evaluated, the trend of a higher rate is the PACEs group continued (both P < .001):
Propensity-score matching, too, among 7839 patient pairs produced higher rates of both mortality outcomes, although the gap did close somewhat (all P < .001):
Diabetes status was shown to have a significant interaction with mortality, too, in that an association for greater 1-year mortality was seen in the first 30 days after surgery among patients in the PACEs group who did not have diabetes (HR, 1.82; 95% CI, 1.56-2.13; P < .001) compared with those who had diabetes (HR, 1.25; 95% CI, 0.98-1.59; P = .08).
“Considering the enormous number of patients undergoing noncardiac surgery and the impact of cardiac complications n these patients, more clinical studies are necessary,” the authors emphasized. “The challenge is to select an optimal end point that is both clinically relevant and not too rare. Our results for incidence and association with long-term mortality may be helpful for selecting an end point in future studies.”
Reference
Oh AR, Park J, Lee JH, et al. Association between perioperative adverse cardiac events and mortality during one‐year follow‐up after noncardiac surgery. J Am Heart Assoc. Published online April 12, 2022. doi:10.1161/JAHA.121.024325
Real-World Data Show Sotorasib Effective for NSCLC With KRAS Mutation
May 18th 2024Data from real-world and clinical-trial settings on frontline monotherapy treatment with the KRAS inhibitor sotorasib both show similar progression-free survivals and a high likelihood that the treatment’s efficacy is not affected with dose reduction.
Read More
Health Equity and Access Weekly Roundup: May 18, 2024
May 18th 2024The US Senate hosted a panel addressing physician and health care shortages and efforts to increase minority representation in the medical field. An expert discussed initiatives to prevent senior homelessness. Advocates called for the repeal of the Comstock Act. Regulatory reforms are called for to improve rural cancer patients' access to pharmacies. Research reveals the impact of denials on patient access to immunology treatments.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Real-World Data Show Sotorasib Effective for NSCLC With KRAS Mutation
May 18th 2024Data from real-world and clinical-trial settings on frontline monotherapy treatment with the KRAS inhibitor sotorasib both show similar progression-free survivals and a high likelihood that the treatment’s efficacy is not affected with dose reduction.
Read More
Health Equity and Access Weekly Roundup: May 18, 2024
May 18th 2024The US Senate hosted a panel addressing physician and health care shortages and efforts to increase minority representation in the medical field. An expert discussed initiatives to prevent senior homelessness. Advocates called for the repeal of the Comstock Act. Regulatory reforms are called for to improve rural cancer patients' access to pharmacies. Research reveals the impact of denials on patient access to immunology treatments.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
2 Commerce Drive
Cranbury, NJ 08512